Julie Chao to Kinins
This is a "connection" page, showing publications Julie Chao has written about Kinins.
Connection Strength
2.593
-
Tissue kallikrein-kinin therapy in hypertension and organ damage. Prog Drug Res. 2014; 69:37-57.
Score: 0.422
-
Tissue kallikrein and kinin infusion promotes neovascularization in limb ischemia. Biol Chem. 2008 Jun; 389(6):725-30.
Score: 0.287
-
Tissue kallikrein and kinin infusion rescues failing myocardium after myocardial infarction. J Card Fail. 2007 Sep; 13(7):588-96.
Score: 0.272
-
Kallikrein/kinin protects against gentamicin-induced nephrotoxicity by inhibition of inflammation and apoptosis. Nephrol Dial Transplant. 2006 Mar; 21(3):624-33.
Score: 0.243
-
Kallikrein-kinin in stroke, cardiovascular and renal disease. Exp Physiol. 2005 May; 90(3):291-8.
Score: 0.227
-
Kallikrein/kinin protects against myocardial apoptosis after ischemia/reperfusion via Akt-glycogen synthase kinase-3 and Akt-Bad.14-3-3 signaling pathways. J Biol Chem. 2005 Mar 04; 280(9):8022-30.
Score: 0.226
-
Expression and cellular localization of tissue kallikrein-kinin system in human adrenal gland. Am J Physiol. 1996 Sep; 271(3 Pt 2):F709-16.
Score: 0.127
-
Kininogen and kinin in experimental spinal cord injury. J Neurochem. 1991 Sep; 57(3):975-80.
Score: 0.090
-
Tissue kallikrein promotes prostate cancer cell migration and invasion via a protease-activated receptor-1-dependent signaling pathway. Biol Chem. 2010 Jul; 391(7):803-12.
Score: 0.083
-
A novel signaling pathway of tissue kallikrein in promoting keratinocyte migration: activation of proteinase-activated receptor 1 and epidermal growth factor receptor. Exp Cell Res. 2010 Feb 01; 316(3):376-89.
Score: 0.079
-
Kallikrein-modified mesenchymal stem cell implantation provides enhanced protection against acute ischemic kidney injury by inhibiting apoptosis and inflammation. Hum Gene Ther. 2008 Aug; 19(8):807-19.
Score: 0.072
-
Experimental therapy with tissue kallikrein against cerebral ischemia. Front Biosci. 2006 May 01; 11:1323-7.
Score: 0.062
-
Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure. Kidney Int. 2000 Aug; 58(2):730-9.
Score: 0.042
-
Enhanced renal function in bradykinin B(2) receptor transgenic mice. Am J Physiol Renal Physiol. 2000 Mar; 278(3):F484-91.
Score: 0.040
-
Kallikrein gene delivery attenuates myocardial infarction and apoptosis after myocardial ischemia and reperfusion. Hypertension. 2000 Jan; 35(1 Pt 1):25-31.
Score: 0.040
-
Human tissue kallikrein attenuates hypertension and secretes into circulation and urine after intramuscular gene delivery in hypertensive rats. Clin Exp Hypertens. 1999 Oct; 21(7):1145-60.
Score: 0.039
-
Adenovirus-mediated kallikrein gene delivery reduces aortic thickening and stroke-induced death rate in Dahl salt-sensitive rats. Stroke. 1999 Sep; 30(9):1925-31; discussion 1931-2.
Score: 0.039
-
Potassium supplement upregulates the expression of renal kallikrein and bradykinin B2 receptor in SHR. Am J Physiol. 1999 03; 276(3):F476-84.
Score: 0.038
-
Molecular cloning and expression of rat bradykinin B1 receptor. Biochim Biophys Acta. 1998 Nov 08; 1442(2-3):177-85.
Score: 0.037
-
Gene therapy in hypertension: adenovirus-mediated kallikrein gene delivery in hypertensive rats. Hum Gene Ther. 1997 Oct 10; 8(15):1753-61.
Score: 0.034
-
New experimental evidence for a role of tissue kallikrein in hypertension. Nephrol Dial Transplant. 1997 Aug; 12(8):1569-74.
Score: 0.034
-
Kallistatin is a potent new vasodilator. J Clin Invest. 1997 Jul 01; 100(1):11-7.
Score: 0.034
-
Molecular cloning and sequence analysis of rat bradykinin B2 receptor gene. Biochim Biophys Acta. 1994 Sep 13; 1219(1):171-4.
Score: 0.028